Long-term effect of intravitreal triamcinolone in the nonproliferative stage of type II idiopathic parafoveal telangiectasia

PURPOSE: To report the visual outcomes and ocular complications of intravitreal triamcinolone acetonide (IVTA) in the treatment of the nonproliferative stage of type II idiopathic parafoveal telangiectasia (IPT). METHODS: Retrospective, multicenter, uncontrolled interventional case series of 19 eyes...

Full description

Autores:
Tipo de recurso:
Fecha de publicación:
2008
Institución:
Universidad del Rosario
Repositorio:
Repositorio EdocUR - U. Rosario
Idioma:
eng
OAI Identifier:
oai:repository.urosario.edu.co:10336/22935
Acceso en línea:
https://doi.org/10.1097/IAE.0b013e31814cf03e
https://repository.urosario.edu.co/handle/10336/22935
Palabra clave:
Triamcinolone
Glucocorticoid
Triamcinolone acetonide
Adult
Aged
Article
Cataract
Cataract extraction
Clinical article
Controlled study
Disease severity
Drug effect
Female
Follow up
Human
Intraocular pressure
Lens implant
Male
Phacoemulsification
Telangiectasia
Treatment outcome
Type 2 idiopathic parafoveal telangiectasia
Visual acuity
Clinical trial
Fluorescence angiography
Injection
Middle aged
Multicenter study
Pathology
Retina blood vessel
Retina disease
Retina fovea
Retrospective study
Telangiectasia
Vitreous body
Aged
Female
Fluorescein angiography
Fovea centralis
Glucocorticoids
Humans
Injections
Male
Middle aged
Retinal diseases
Retinal vessels
Retrospective studies
Telangiectasis
Treatment outcome
Triamcinolone acetonide
Visual acuity
Vitreous body
Juxtafoveolar telangiectasis
Macular edema
Macular telangiectasia
Parafoveal telangiectasis
Perifoveal telangiectasia
Triamcinolone
Rights
License
Abierto (Texto Completo)
Description
Summary:PURPOSE: To report the visual outcomes and ocular complications of intravitreal triamcinolone acetonide (IVTA) in the treatment of the nonproliferative stage of type II idiopathic parafoveal telangiectasia (IPT). METHODS: Retrospective, multicenter, uncontrolled interventional case series of 19 eyes of 14 consecutive patients with the nonproliferative stage of IPT that had undergone at least one intravitreal injection of 4 mg of triamcinolone acetonide. Demographic, medical, and ocular data were obtained through chart review. The main outcome measures included best-corrected visual acuity at several timepoints of follow up and ocular complications. RESULTS: At baseline the mean logMAR visual acuity was 0.83 ± 0.41 (Snellen 20/135, range 0.3-2). After an average follow-up of 21.2 months (range 6-44 months), the mean logMAR visual acuity remained essentially unchanged from baseline. At 3 months, the logMAR visual acuity was 0.86 ± 0.44 (Snellen 20/145, P = 0.8378), at 6 months 0.86 ± 0.42 (Snellen 20/145, P = 0.8149), at 12 months 0.87 ± 0.46 (Snellen 20/148, P > 0.9999), at 18 months 0.84 ± 0.35 (Snellen 20/138, P = 0.8385), and at the last follow-up 0.82 ± 0.44 (Snellen 20/132, P = 0.9301). Seven eyes were reinjected once. Ten of 19 eyes (53%) developed cataract (3 eyes underwent phacoemulsification and intraocular lens implantation) and 7 of 19 eyes (37%) had an elevated intraocular pressure, none of which required surgical treatment. CONCLUSION: IVTA does not seem to improve visual acuity in most eyes with the nonproliferative stage of IPT. © The Ophthalmic Communications Society, Inc.